We estimate that the CEO of Immunovant, Inc. ($IMVT), Eric Venker, received a compensation of $20,158,767 in 2026.
These estimates are based on a new DEF14A filing, filed with the SEC on July 22, 2026. Note that parsing errors may occur.
You can track $IMVT on Quiver Quantitative's $IMVT stock dashboard.
$IMVT Stock Insider Trading Activity
$IMVT Stock insiders have traded $IMVT stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- ANDREW J. FROMKIN has made 0 purchases and 2 sales selling 221,951 shares for an estimated $7,438,111.
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 10 sales selling 58,350 shares for an estimated $2,054,846.
- TIAGO GIRAO (Chief Financial Officer) has made 0 purchases and 2 sales selling 35,760 shares for an estimated $1,147,611.
- MELANIE GLORIA (Chief Operating Officer) has made 0 purchases and 8 sales selling 31,710 shares for an estimated $1,065,886.
- TUYL CHRISTOPHER VAN (Chief Legal Officer) has made 0 purchases and 7 sales selling 29,706 shares for an estimated $1,023,891.
- ERIC VENKER (Chief Executive Officer) has made 0 purchases and 3 sales selling 17,321 shares for an estimated $461,834.
- ATUL PANDE has made 0 purchases and 3 sales selling 9,000 shares for an estimated $300,045.
- ROBERT GRAHAM SUSMAN sold 2,502 shares for an estimated $67,979
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IMVT Stock Hedge Fund Activity
We have seen 117 institutional investors add shares of $IMVT Stock stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 2,797,055 shares (+168.4%) to their portfolio in Q1 2026, for an estimated $68,933,420
- JENNISON ASSOCIATES LLC added 2,496,241 shares (+356.4%) to their portfolio in Q1 2026, for an estimated $61,519,859
- ARMISTICE CAPITAL, LLC removed 2,182,239 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $53,781,280
- POINT72 ASSET MANAGEMENT, L.P. removed 2,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $49,290,000
- FARALLON CAPITAL MANAGEMENT LLC added 1,534,000 shares (+12783.3%) to their portfolio in Q1 2026, for an estimated $37,805,430
- MORGAN STANLEY removed 969,508 shares (-20.0%) from their portfolio in Q1 2026, for an estimated $23,893,524
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 880,000 shares (-79.3%) from their portfolio in Q1 2026, for an estimated $21,687,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IMVT Stock Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 6 analysts offer price targets for $IMVT in the last 6 months, with a median target of $41.5.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $61.0 on 06/30/2026
- Yatin Suneja from Guggenheim set a target price of $62.0 on 05/26/2026
- Danielle Brill from Truist Securities set a target price of $30.0 on 05/22/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $40.0 on 05/21/2026
- Jason Gerberry from B of A Securities set a target price of $43.0 on 05/21/2026
- Corinne Johnson from Goldman Sachs set a target price of $32.0 on 04/15/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
